시장보고서

상품코드

1498540

약물동태 서비스 시장 규모 및 예측, 세계 및 지역 점유율, 동향, 성장 기회 분석 보고서 : 약물 유형별, 서비스 유형별, 치료 용도별, 최종사용자별, 지역별

Pharmacokinetics Services Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Type, Service Type, Therapeutic Application, and End User, and Geography

발행일: 2024년 05월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 174 Pages | 배송안내 : 즉시배송

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

약물동태 서비스 시장 규모는 2023년 8억 7,496만 달러에서 2031년 15억 7,987만 달러에 달할 것으로 예상되며, 2023-2031년 연평균 7.6%의 CAGR을 기록할 것으로 예측됩니다.

약물동태 서비스 시장의 시장 촉진요인

만성질환 및 감염성 질환의 유병률 증가

당뇨병, 암, 자가면역질환과 같은 만성질환의 유병률 증가는 전 세계적으로 의약품 개발 노력을 촉진하는 요인이 되고 있습니다. 세계보건기구(WHO)의 2024년 자료에 따르면 전 세계 4억 2,200만 명이 당뇨병을 앓고 있으며, 주로 중저소득 국가에서 주로 발생하며 매년 약 150만 명이 사망하고 있습니다. 제약회사는 다양한 질병에 대한 치료제 개발의 최전선에 있습니다. 약물동태 연구는 인체 내 흡수, 분포, 대사 및 배설(ADME) 과정을 분석하여 이러한 약물이 환자의 신체에서 어떻게 작용하는지 이해하는 데 필수적입니다. 약물의 전신 순환으로의 흡수는 약물이 작용 부위(예: 혈장)에 도달하는 속도와 농도에 영향을 미칩니다. 약물의 전신 분포 패턴은 약물의 생화학적 특성과 신체 생리학에 따라 달라집니다. 대사는 약물이 체내에서 처리되어 후속 화합물로 전환되는 과정을 포함합니다. 이 단계는 약물을 수용성 물질로 전환하고 신장 제거에 적합한 상태로 만드는 데 중요합니다. 대사는 또한 코데인과 같은 전구 약물을 활성 대사 산물로 전환하는 데에도 중요합니다. 체내에서 약물의 배설은 주로 신장을 통해 이루어지지만 폐, 피부, 소화관을 통해 배설될 수 있으며, ADME 동역학은 체내에서 약물의 생체 이용률을 규정하고 약물의 유지 용량은 클리어런스 시간(원하는 혈장 농도 ÷ 생체 이용률)에 따라 계산됩니다. 클리어런스를 이해하면 당업자는 적절한 투여 속도를 계산할 수 있습니다.

약물동태 시험은 약물의 효과와 안전성을 이해하기 위해 피험자의 약물 투여 요법을 최적화하는 데 초점을 맞추고 있습니다. 이러한 시험은 장기 치료용으로 개발된 약물의 안전성을 보장하는 데 필수적이며, 만성 질환 관리에서 약물 제제의 적합성과 안정성을 평가하는 데 도움이 됩니다. 따라서 만성질환과 감염성 질환의 증가로 인해 안전하고 효과적인 맞춤형 치료제를 개발하기 위한 약물동태 시험의 중요성이 강조되고 있습니다.

약물동태 서비스 시장에서의 기회

의약품 제조 시 발생하는 방대한 약물동태 데이터를 수집하고 처리하는 것은 비용이 많이 들고 번거롭고 시간이 많이 소요되는 작업입니다. 이러한 작업은 많은 노력과 비용이 들기 때문에 약물동태 시뮬레이션 모델이나 in vitro-in vivo 약물동태 상관관계 모델(IVIVC)과 같은 약물동태 시뮬레이션 모델의 필요성이 부각되고 있습니다. 약물동태 시뮬레이션 모델은 계산 및 수학적 모델을 사용하여 특정 조건에서 생활 환경에서의 약물동태을 해석하는 도구입니다. 또한, IVIVC 모델은 신약개발 과정의 기본적인 부분입니다. 의약품 개발 초기 단계에서 PK/PD 예측을 분석하는 것은 리드 화합물의 최적화 전략에 필요하며, 감소율을 더욱 낮추기 위해서도 필요합니다. 약물동태 특성을 개선하고 특성화하기 위한 새로운 in-vitro 및 in-vivo 전략의 개발에서 상당한 진전이 이루어지고 있으며, IVIVC 모델은 약물의 생체 이용률과 그 적용을 분석하는 생약학적 특성을 평가하기 위한 비용 효율적인 옵션으로 제안되고 있습니다. 따라서 이러한 in-vivo 및 in-vitro 모델은 가까운 장래에 약물동태 서비스 시장에 유리한 기회를 제공할 것으로 예상됩니다.

약물동태 서비스 시장 부문별 개요

약물 유형별로 시장은 저분자, 고분자, 백신으로 구분되며, 2023년에는 저분자 부문이 가장 큰 시장 점유율을 차지했습니다.

약물동태 서비스 시장은 치료 용도별로 암, 감염성 질환, 신경질환, 자가면역질환, 부인과 질환, 심혈관계 질환, 호흡기 질환, 기타로 분류되며, 2023년에는 암 분야가 가장 큰 시장 점유율을 차지했습니다.

약물동태 서비스 시장 지리적 개요

북미가 가장 큰 점유율을 차지하고 있습니다. 캐나다 정부 보고서에 따르면 캐나다 보건부는 신약(백신 포함)을 시험하고 승인된 의약품의 새로운 용도를 도입하기 위해 수백 건의 새로운 임상시험 신청서를 접수했습니다. 캐나다 내 소아 환자(소아 및 청소년)는 부모의 허락을 받아 임상시험에 참여합니다. 캐나다 보건부는 소아 및 청소년을 포함한 임상시험에 참여하는 개인을 보호하고 있습니다. 캐나다 임상시험 자산 지도(CCTAM) 보고서에 따르면 캐나다에서는 2022년까지 약 3,500건의 임상시험이 등록되며, 그 중 암 치료제는 중요한 중점 분야로 2021년에는 1,300건의 암 임상시험이 등록되었습니다. Innovative Medicines Canada의 보고서에 따르면 제약업계는 캐나다 임상연구에 12억 달러를 투자했다. 또한 캐나다 임상시험 네트워크(CCTN)는 2021년 현재 600만 명 이상의 환자 기록을 관리하고 있습니다. 이처럼 캐나다의 의약품 개발 및 발견 프로젝트가 급증함에 따라 약물동태 서비스에 대한 수요는 증가할 것입니다. 이처럼 임상시험 및 조사 연구의 증가, 감염성 질환 및 만성 질환의 유병률 증가는 캐나다의 약물동태 서비스 시장의 성장을 촉진하는 요인 중 하나입니다.

약물동태 서비스 시장 - 주요 시장 역학
시장 성장 촉진요인
- 만성질환 및 감염증 유병률 상승
- 약물동태 시험 적용 범위 확대
- CRO에 약물동태 서비스 아웃소싱
시장 성장 억제요인
- 신흥 국가의 약물동태 서비스 프로바이더의 제한적인 도달 범위
시장 기회
- 약물동태 격차를 이해하기 위한 생체내 및 생체외 모델 채용 증가
향후 동향
- 약물동태 서비스의 빅데이터 분석 채용 증가
성장 촉진요인과 저해요인의 영향

제6장 약물동태 서비스 시장 - 세계 시장 분석

약물동태 서비스 시장 매출, 2023-2031년

제7장 약물동태 서비스 시장 분석 : 약물 유형별

저분자
대분자
백신

제8장 약물동태 서비스 시장 분석 : 서비스 유형별

전임상 ADME 및 인간 시험
PK/PD 분석과 리포팅
투여 시뮬레이션
리스크 분석
기타

제9장 약물동태 서비스 시장 분석 : 치료 용도별

암영역
감염증
신경질환
자가면역질환
부인과 질환
순환기질환
호흡기질환
기타

제10장 약물동태 서비스 시장 분석 : 최종사용자별

제약 기업 및 바이오테크놀러지 기업
수탁연구기관
기타

제11장 약물동태 서비스 시장 : 지역별 분석

북미
- 미국
- 캐나다
- 멕시코
유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 기타 유럽
아시아태평양
- 중국
- 일본
- 인도
- 호주
- 한국
- APAC 기타
중동 및 아프리카
- 사우디아라비아
- 남아프리카공화국
- 아랍에미리트
- 기타 중동 및 아프리카
중남미
- 브라질
- 아르헨티나
- 기타 중남미

제12장 기업 개요

Charles River Laboratories International Inc
Eurofins Scientific SE
Evotec SE
Certara Inc.
Parexel International Corp
Thermo Fisher Scientific Inc.
Allucent
PACIFIC BIOLABS
SGS SA
Shanghai Medicilon Inc.

제13장 부록

ksm 24.06.26

The pharmacokinetics services market size is projected to reach US$ 1,579.87 million by 2031 from US$ 874.96 million in 2023. The market is expected to register a CAGR of 7.6% during 2023-2031.

Market Drivers of the Pharmacokinetics Services Market

Rising Prevalence of Chronic and Infectious Diseases

The growing prevalence of chronic diseases such as diabetes, cancer, and autoimmune diseases has been a prime enabler of drug development efforts across the world. According to the World Health Organization's (WHO) 2024 data, ~422 million in the world suffer from diabetes, and these cases are mostly found in middle and low-income countries, causing approximately 1.5 million deaths every year. Pharmaceutical companies are at the forefront of developing drugs to treat various diseases. Pharmacokinetic studies are essential for understanding how these drugs behave in a patient's body by analyzing the process of absorption, distribution, metabolization, and elimination (ADME) within the human body. The absorption of a drug into systemic circulation affects the speed and concentration at which a drug may reach the site of action, e.g., plasma. Drug distribution pattern throughout the body varies based on its biochemical properties and body physiology. Metabolism involves the processing of the drug by the body into subsequent compounds. This step is instrumental in converting the drug into water-soluble substances to render them suitable for renal clearance. Metabolism is also important for the conversion of prodrugs, such as codeine, into active metabolites. Excretion of drugs from the body is mainly governed by kidneys; however, in several cases, drugs may be excreted via the lungs, skin, or gastrointestinal tract. ADME dynamics define the bioavailability of drugs in the body, and the maintenance doses of drugs are calculated based on their clearance times (desired plasma concentration divided by bioavailability). Understanding of clearance allows practitioners to calculate appropriate dosing rates.

Pharmacokinetic studies focus on optimizing drug dose regimens in study subjects to understand the efficacy and safety of a drug. These studies are essential for ensuring the safety of drugs that are developed for long-term treatments, which helps evaluate the suitability and stability of drug formulations in chronic disease management. Hence, the rising burden of chronic and infectious diseases underlines the importance of pharmacokinetic studies to develop safe and effective personalized treatments.

Opportunities in the Pharmacokinetics Services Market

The collection and handling of huge pharmacokinetic data generated during drug manufacturing are expensive, tedious, and time-consuming tasks. The labor- and cost-intensive nature of these tasks highlights the need for models such as pharmacokinetic simulation models and in vitro-in vivo pharmacokinetic correlation models (IVIVC) for the prediction of pharmacokinetic parameters. The pharmacokinetic simulation model is a tool that interprets drug kinetics in the living environment under specific conditions using computational and mathematical models. In addition, the IVIVC model are a fundamental part of the drug discovery process. Analyzing PK/PD predictions at the early stages of drug development is necessary for lead optimization strategies and also to further reduce attrition rates. There have been significant advancements in the development of new in-vitro and in-vivo strategies to improve and characterize pharmacokinetic properties. IVIVC models are being proposed as a cost-effective alternative to assess the biopharmaceutical properties that analyze the bioavailability of drugs and their application. Hence, such in-vivo and in-vitro models are anticipated to provide lucrative opportunities for the pharmacokinetics services market in the near future.

Pharmacokinetics Services Market: Segmental Overview

By drug type, the market is segmented into small molecules, large molecules, and vaccines. The small molecule segment held the largest market share in 2023.

The pharmacokinetics services market, by therapeutic application, is categorized into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.

Pharmacokinetics Services Market: Geographical Overview

North America held the largest share of the market. According to a report by the Government of Canada, Health Canada receives hundreds of new clinical trial applications to test new drugs (including vaccines) or to introduce new uses of approved medicines. Pediatric patients (children and youth) in the country participate in clinical trials with their parents' permission. Health Canada protects individuals participating in clinical trials, including children and youth. According to the Canadian Clinical Trials Asset Map (CCTAM) report, ~3,500 clinical trials were registered in Canada in 2022, with cancer therapeutics being a significant area of focus, accounting for 1,300 cancer clinical trials in 2021. The pharmaceutical industry invested ~US$ 1.2 billion in clinical research in Canada, per the Innovative Medicines Canada report. Further, the Canadian Clinical Trials Network (CCTN) had over 6 million patient records maintained as of 2021. Thus, the demand for pharmacokinetic services increases with the surge in drug development and discovery projects in Canada. Thus, the rising number of clinical trials and research studies, and the increasing prevalence of infectious diseases and chronic disorders are among the factors propelling the pharmacokinetics services market growth in Canada.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Pharmacokinetics Services Market Landscape

4.1 PEST Analysis

5. Pharmacokinetics Services Market - Key Market Dynamics

5.1 Pharmacokinetics Services Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Rising Prevalence of Chronic and Infectious Diseases
- 5.2.2 Expanding Range of Application of Pharmacokinetic Studies
- 5.2.3 Outsourcing of Pharmacokinetics Services to CROs
5.3 Market Restraints
- 5.3.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
5.4 Market Opportunities
- 5.4.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
5.5 Future Trend
- 5.5.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
5.6 Impact of Drivers and Restraints:

6. Pharmacokinetics Services Market - Global Market Analysis

6.1 Pharmacokinetics Services Market Revenue (US$ Million), 2023-2031

7. Pharmacokinetics Services Market Analysis - by Drug Type

7.1 Overview
7.2 Small Molecule
- 7.2.1 Overview
- 7.2.2 Small Molecule: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Large Molecule
- 7.3.1 Overview
- 7.3.2 Large Molecule: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Vaccines
- 7.4.1 Overview
- 7.4.2 Vaccines: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8. Pharmacokinetics Services Market Analysis - by Service Type

8.1 Pre-Clinical ADME and Human Studies
- 8.1.1 Overview
- 8.1.2 Pre-Clinical ADME and Human Studies: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.2 PK/PD Analysis and Reporting
- 8.2.1 Overview
- 8.2.2 PK/PD Analysis and Reporting: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Dosing Simulations
- 8.3.1 Overview
- 8.3.2 Dosing Simulations: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Risk Analysis
- 8.4.1 Overview
- 8.4.2 Risk Analysis: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9. Pharmacokinetics Services Market Analysis - by Therapeutic Application

9.1 Oncology
- 9.1.1 Overview
- 9.1.2 Oncology: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Infectious Diseases
- 9.2.1 Overview
- 9.2.2 Infectious Diseases: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Neurological Disorders
- 9.3.1 Overview
- 9.3.2 Neurological Disorders: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.4 Autoimmune Diseases
- 9.4.1 Overview
- 9.4.2 Autoimmune Diseases: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.5 Gynecological Disorders
- 9.5.1 Overview
- 9.5.2 Gynecological Disorders: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.6 Cardiovascular Diseases
- 9.6.1 Overview
- 9.6.2 Cardiovascular Diseases: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.7 Respiratory Disorders
- 9.7.1 Overview
- 9.7.2 Respiratory Disorders: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.8 Others
- 9.8.1 Overview
- 9.8.2 Others: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10. Pharmacokinetics Services Market Analysis - by End User

10.1 Pharmaceutical and Biotechnology Companies
- 10.1.1 Overview
- 10.1.2 Pharmaceutical and Biotechnology Companies: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Contract Research Organization
- 10.2.1 Overview
- 10.2.2 Contract Research Organization: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Others
- 10.3.1 Overview
- 10.3.2 Others: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

11. Pharmacokinetics Services Market - Geographical Analysis

11.1 North America
- 11.1.1 North America Pharmacokinetics Services Market Overview
- 11.1.2 North America: Pharmacokinetics Services Market - Revenue and Forecast Analysis - by Country
  - 11.1.2.1 United States: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.2.1.1 Overview
    - 11.1.2.1.2 United States: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.2.1.3 United States: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.1.2.1.4 United States: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.1.2.1.5 United States: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.1.2.1.6 United States: Pharmacokinetics Services Market Breakdown, by End User
  - 11.1.2.2 Canada: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.2.2.1 Overview
    - 11.1.2.2.2 Canada: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.2.2.3 Canada: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.1.2.2.4 Canada: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.1.2.2.5 Canada: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.1.2.2.6 Canada: Pharmacokinetics Services Market Breakdown, by End User
  - 11.1.2.3 Mexico: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.2.3.1 Overview
    - 11.1.2.3.2 Mexico: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.2.3.3 Mexico: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.1.2.3.4 Mexico: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.1.2.3.5 Mexico: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.1.2.3.6 Mexico: Pharmacokinetics Services Market Breakdown, by End User
11.2 Europe
- 11.2.1 Europe Pharmacokinetics Services Market Overview
- 11.2.2 Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.2.3 Pharmacokinetics Services Market Breakdown by Countries
- 11.2.4 Pharmacokinetics Services Market Revenue and Forecast and Analysis - by Country
  - 11.2.4.1 Germany: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.4.1.1 Overview
    - 11.2.4.1.2 Germany: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.4.1.3 Germany: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.2.4.1.4 Germany: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.2.4.1.5 Germany: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.2.4.1.6 Germany: Pharmacokinetics Services Market Breakdown, by End User
  - 11.2.4.2 France: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.4.2.1 Overview
    - 11.2.4.2.2 France: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.4.2.3 France: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.2.4.2.4 France: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.2.4.2.5 France: Pharmacokinetics Services Market Breakdown, by Therapeutic Application

The market for infectious diseases segment is estimated to be worth US$ 19.24 million by 2031 and is expected to register a CAGR of 10.8% during the 2023-2031.

11.2.4.2.6 France: Pharmacokinetics Services Market Breakdown, by End User

11.2.4.3 United Kingdom: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.2.4.3.1 Overview
- 11.2.4.3.2 United Kingdom: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.2.4.3.3 United Kingdom: Pharmacokinetics Services Market Breakdown, by Drug Type
- 11.2.4.3.4 United Kingdom: Pharmacokinetics Services Market Breakdown, by Service Type
- 11.2.4.3.5 United Kingdom: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
- 11.2.4.3.6 United Kingdom: Pharmacokinetics Services Market Breakdown, by End User
11.2.4.4 Italy: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.2.4.4.1 Overview
- 11.2.4.4.2 Italy: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.2.4.4.3 Italy: Pharmacokinetics Services Market Breakdown, by Drug Type
- 11.2.4.4.4 Italy: Pharmacokinetics Services Market Breakdown, by Service Type
- 11.2.4.4.5 Italy: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
- 11.2.4.4.6 Italy: Pharmacokinetics Services Market Breakdown, by End User
11.2.4.5 Spain: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.2.4.5.1 Overview
- 11.2.4.5.2 Spain: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.2.4.5.3 Spain: Pharmacokinetics Services Market Breakdown, by Drug Type
- 11.2.4.5.4 Spain: Pharmacokinetics Services Market Breakdown, by Service Type
- 11.2.4.5.5 Spain: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
- 11.2.4.5.6 Spain: Pharmacokinetics Services Market Breakdown, by End User
11.2.4.6 Rest of Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.2.4.6.1 Overview
- 11.2.4.6.2 Rest of Europe: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.2.4.6.3 Rest of Europe: Pharmacokinetics Services Market Breakdown, by Drug Type
- 11.2.4.6.4 Rest of Europe: Pharmacokinetics Services Market Breakdown, by Service Type
- 11.2.4.6.5 Rest of Europe: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
- 11.2.4.6.6 Rest of Europe: Pharmacokinetics Services Market Breakdown, by End User

11.3 Asia Pacific
- 11.3.1 Asia Pacific Pharmacokinetics Services Market Overview
- 11.3.2 Asia Pacific: Pharmacokinetics Services Market
- 11.3.3 Asia Pacific: Pharmacokinetics Services Market - Revenue and Forecast Analysis - by Country
  - 11.3.3.1 China: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.1.1 Overview
    - 11.3.3.1.2 China: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.1.3 China: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.3.3.1.4 China: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.3.3.1.5 China: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.3.3.1.6 China: Pharmacokinetics Services Market Breakdown, by End User
  - 11.3.3.2 Japan: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.2.1 Overview
    - 11.3.3.2.2 Japan: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.2.3 Japan: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.3.3.2.4 Japan: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.3.3.2.5 Japan: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.3.3.2.6 Japan: Pharmacokinetics Services Market Breakdown, by End User
  - 11.3.3.3 India: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.3.1 Overview
    - 11.3.3.3.2 India: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.3.3 India: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.3.3.3.4 India: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.3.3.3.5 India: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.3.3.3.6 India: Pharmacokinetics Services Market Breakdown, by End User
  - 11.3.3.4 Australia: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.4.1 Overview
    - 11.3.3.4.2 Australia: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.4.3 Australia: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.3.3.4.4 Australia: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.3.3.4.5 Australia: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.3.3.4.6 Australia: Pharmacokinetics Services Market Breakdown, by End User
  - 11.3.3.5 South Korea: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.5.1 Overview
    - 11.3.3.5.2 South Korea: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.5.3 South Korea: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.3.3.5.4 South Korea: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.3.3.5.5 South Korea: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.3.3.5.6 South Korea: Pharmacokinetics Services Market Breakdown, by End User
  - 11.3.3.6 Rest of APAC: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.6.1 Overview
    - 11.3.3.6.2 Rest of APAC: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.6.3 Rest of APAC: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.3.3.6.4 Rest of APAC: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.3.3.6.5 Rest of APAC: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.3.3.6.6 Rest of APAC: Pharmacokinetics Services Market Breakdown, by End User
11.4 Middle East and Africa
- 11.4.1 Middle East and Africa Pharmacokinetics Services Market Overview
- 11.4.2 Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.4.3 Pharmacokinetics Services Market Breakdown by Countries
- 11.4.4 Pharmacokinetics Services Market Revenue and Forecast and Analysis - by Country
- 11.4.5 Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast Analysis - by Country
  - 11.4.5.1 Saudi Arabia: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.5.1.1 Overview
    - 11.4.5.1.2 Saudi Arabia: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.5.1.3 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.4.5.1.4 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.4.5.1.5 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.4.5.1.6 Saudi Arabia: Pharmacokinetics Services Market Breakdown, by End User
  - 11.4.5.2 South Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.5.2.1 Overview
    - 11.4.5.2.2 South Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.5.2.3 South Africa: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.4.5.2.4 South Africa: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.4.5.2.5 South Africa: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.4.5.2.6 South Africa: Pharmacokinetics Services Market Breakdown, by End User
  - 11.4.5.3 United Arab Emirates: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.5.3.1 Overview
    - 11.4.5.3.2 United Arab Emirates: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.5.3.3 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.4.5.3.4 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.4.5.3.5 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.4.5.3.6 United Arab Emirates: Pharmacokinetics Services Market Breakdown, by End User
  - 11.4.5.4 Rest of Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.5.4.1 Overview
    - 11.4.5.4.2 Rest of Middle East and Africa: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.5.4.3 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.4.5.4.4 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.4.5.4.5 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.4.5.4.6 Rest of Middle East and Africa: Pharmacokinetics Services Market Breakdown, by End User
11.5 South and Central America
- 11.5.1 South and Central America Pharmacokinetics Services Market Overview
- 11.5.2 South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.5.3 Pharmacokinetics Services Market Breakdown by Countries
- 11.5.4 Pharmacokinetics Services Market Revenue and Forecast and Analysis - by Country
  - 11.5.4.1 Brazil: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.4.1.1 Overview
    - 11.5.4.1.2 Brazil: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.4.1.3 Brazil: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.5.4.1.4 Brazil: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.5.4.1.5 Brazil: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.5.4.1.6 Brazil: Pharmacokinetics Services Market Breakdown, by End User
  - 11.5.4.2 Argentina: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.4.2.1 Overview
    - 11.5.4.2.2 Argentina: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.4.2.3 Argentina: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.5.4.2.4 Argentina: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.5.4.2.5 Argentina: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.5.4.2.6 Argentina: Pharmacokinetics Services Market Breakdown, by End User
  - 11.5.4.3 Rest of South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.4.3.1 Overview
    - 11.5.4.3.2 Rest of South and Central America: Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.4.3.3 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by Drug Type
    - 11.5.4.3.4 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by Service Type
    - 11.5.4.3.5 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 11.5.4.3.6 Rest of South and Central America: Pharmacokinetics Services Market Breakdown, by End User

12. Company Profile

12.1 Charles River Laboratories International Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Eurofins Scientific SE
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Evotec SE
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Certara Inc.
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
12.5 Parexel International Corp
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Thermo Fisher Scientific Inc.
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Allucent
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 PACIFIC BIOLABS
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 SGS SA
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Shanghai Medicilon Inc.
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About The Insight Partners